Every reference with a DOI in the deposited reference list resolved to a known
work in Crossref or DataCite at the dated check, and none carried a retraction,
withdrawal, or removal notice.
The 34 checked references that resolve
resolves10.1089/cap.2012.0058An Open-Label Extension Study of the Safety and Efficacy of Risperidone in Children and Adolescents with Autistic Disorder
resolves10.4103/0253-7176.127254Effects of Risperidone on Core Symptoms of Autistic Disorder Based on Childhood Autism Rating Scale: An Open Label Study
resolves10.1089/104454604773840472Risperidone Treatment of Children with Autistic Disorder: Effectiveness, Tolerability, and Pharmacokinetic Implications
resolves10.1177/0091270009347867Effect of CYP2D6, CYP3A5, and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and Its Active Moiety
resolves10.1097/JCP.0b013e3181a289e0Effects of CYP2D6 and CYP3A5 Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients
resolves10.1097/JCP.0b013e31828ecd52Impact of the ABCB1 Gene Polymorphism on Plasma 9-Hydroxyrisperidone and Active Moiety Levels in Japanese Patients With Schizophrenia
resolves10.1007/s00228-010-0850-1The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone
resolves10.1111/dmcn.12470<scp>CYP</scp>2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study
resolves10.1038/tpj.2009.63Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions
resolves10.1016/j.dmpk.2016.01.005Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels
resolves10.1002/jcla.22009Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9‐Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders
resolves10.1089/cap.2000.10.79Long-Term Risperidone for Pervasive Developmental Disorder: Efficacy, Tolerability, and Discontinuation
resolves10.1038/sj.mp.4000350The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers
resolves10.1038/sj.mp.4000343D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene
resolves10.1097/JCP.0b013e31822c09a7Comparing the Influence of Dopamine D2 Polymorphisms and Plasma Drug Concentrations on the Clinical Response to Risperidone
resolves10.1016/j.psychres.2016.04.001Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia
resolves10.1097/JCP.0000000000000474Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders
resolves10.1097/FTD.0b013e3181858ca9ABCB1 Polymorphisms Influence Steady-State Plasma Levels of 9-Hydroxyrisperidone and Risperidone Active Moiety
resolves10.2217/14622416.7.7.987Polymorphisms of the<i>ABCB1</i>Gene are Associated with the Therapeutic Response to Risperidone in Chinese Schizophrenia Patients
resolves10.1097/00004850-200503000-00002Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6
resolves10.1111/bph.12295Signalling profile differences: paliperidone versus risperidone
resolves10.1124/jpet.111.189076Relationship between Dose, Drug Levels, and D2 Receptor Occupancy for the Atypical Antipsychotics Risperidone and Paliperidone
resolves10.1093/hmg/6.4.577A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia
resolves10.1073/pnas.0508189103A functional variant of the dopamine D
<sub>3</sub>
receptor is associated with risk and age-at-onset of essential tremor
resolves10.1089/cap.2015.0005Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial
resolves10.1159/000287535Depression, Hostility and Anxiety in Hyperprolactinemic Amenorrhea
The 5 references without a DOI — listed, not checked
no DOI — not checkedAutism: Recognition, Referral and Diagnosis of Children and Young People on the Autism Spectrum
no DOI — not checkedGoodman and Gilman's The Pharmacological Basis of Therapeutics
no DOI — not checkedMDR1 (ABCB1) polymorphisms: functional effects and clinical implications
no DOI — not checkedHyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone
no DOI — not checkedStudies on the neuroendocrine role of serotonin
checked 2026-07-23 — re-checked daily as this page is visited;
titles and statuses come from Crossref and DataCite and are not part of the signed record
Both snippets point at the live badge image and link back to this page. The
badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.